Guidelines for anti-aggregative therapy by acetylsalicylic acid. Czech Society of Gastroenterology Statement

Czech version

Authors: M. Lukáš ¹; J. Špičák ²; R. Keil ³
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty, ISCARE a 1. LF UK v Praze a Ústav klinické biochemie a laboratorní diagnostiky, 1. LF UK v Praze ¹; Klinika hepato-gastroenterologie, IKEM, Praha ²; Interní klinika FN Motol a 2. LF UK v Praze ³
Published in: Gastroent Hepatol 2013; 67(2): 90-94
Category:

Sources

1. Graham GB. Antithrombotics trialist corporation. Lancet 2009; 373(9678): 1849–1860.

2. Hradec J, Býma S. Ischemická choroba srdeční, Doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře,CDP-PL, 2009.

3. Douthweit H, Lintott GAM. Gastroscopic observation of effect of aspirin and certein ather substances on the stomach. Lancet 1938; 2 : 1222–1225.

4. Bode-Boger SD, Boger RH, Schubert M et al. Effects of very low dose and enteric--coated acetylsalicyc acid on prostacycline and thromboxane formation on bleeding time in healthy subjects. Eur J Clin Pharmacol 1998; 54(9–10): 707–714.

5. Darius H. Anwendungsbeobachtung dokumentiert gute Vertraglichkeit. Pharmazie 2006; 34 : 3090–3098.

6. Lukáš M, Chalupná P. Masivní krvácení z horní části trávicí trubice, indukované nesteroidními antirevmatiky. Endoskopie 2001; 10(2): 32–38.

7. Taha AS, Angerson WJ, Knill-Jones RP et al. Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs–a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2005; 22(4): 285–289.

8. Taha AS, Angerson WJ, Prasad R et al. Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti-inflammatory drugs and low-dose aspirin. Aliment Pharmacol Ther 2007; 26(8): 1171–1178.

9. Martínek J, Lukáš M. Inhibitory protonové pumpy „up to date“. Gastroenterol Hepatol 2011; 65(6): 331–342.

10. Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104(3): 728–738.

11. Dammann HG. Gastroduodenal tolerability profile of low enteric coated ASA. Gastroenterology International 1998; 11(4): 205–216.

12. Chan FKL, Ching JYL, Suen BY et al. Effects of Helicobacter pylori infection on long--term risk of peptic ulcer bleeding in low-dose aspirin users. Gastro 2013; 144(3): 528–535.

13. Malfertheiner P, Megraud F, O’Morain C et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012; 61(5): 646–664.

14. Lanas A, Perez-Aisa MA, Feu F et al. A nation study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 2005; 100(8): 1685–11693.

15. Steering Committee of the Physicians Health Study Research Group . Final report on the aspirin component of the ongoing Physician’s Health Study. N Engl J Med 1989; 321(3): 129–135.

16. Slattery J, Warlow CP, hSorrock CJ et al. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin –⁠ analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995; 37(4): 509–511.

17. Naschitz JE, Yeshurun B, Odeh M et al. Overt gastrointestinal bleeding in the course of chronic low dose aspirin administration for secondary prevention of arterial occlusive disease. Am J Gastroenterol 1990; 85(4): 408–411.

18. Kurata JH, Abbey DE. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol 1990; 12(3): 260–266.

19. McQuaid KR, Laine L. Systemic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119(8): 624–638.

20. Serrano P, Lanas A, Arroyo MT et al. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002; 16(11): 1945–1953.

21. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin —⁠ what’s the risk? Aliment Pharmacol Ther 2006; 24(6): 897–908.

22. Van Soest EM, Valkhoff VE, Mazzaglia G et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using free European databases. Gut 2011; 60(12): 1650–1659.

23. Valkhoff VE, van Soest EM, Sturkenboom MC et al. Time-trends in gastroprotection with nonsteroidal antiinflammatory drugs (NSAIDs). Aliment Pharmacol Ther 2010; 31(11): 1218–1228.

24. Lopez-Pintor E, Lumbreras B. Use of gastrointestinal prophylaxis in NSAID patients: a cross sectional study in community pharmacies. Int J Clin Pharm 2011; 33(2): 155–164.

25. Wong GL, Wong VW, Chan Y et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori--negative idiopathic bleeding ulcers. Gastroenterology 2009; 137(2): 525–531.

26. Ng SC, Chan FK. NSAID-induced gastrointestinal and cardiovascular injury. Curr Opin Gastroenterol 2010; 26(6): 611–617.

27. Ho CW, Tse YK, Wu B et al. The use of prophylactic gastroprotective therapy in patients with nonsteroidal anti-inflammatory drug -⁠ and aspirin-associated ulcer bleeding: a cross-sectional study. Aliment Pharmacol Ther 2013; 37(8): 819–824.